摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-溴-n-乙基-5-硝基-4-吡啶胺 | 913642-07-6

中文名称
2-溴-n-乙基-5-硝基-4-吡啶胺
中文别名
——
英文名称
2-bromo-N-ethyl-5-nitro-4-pyridinamine
英文别名
2-bromo-N-ethyl-5-nitropyridin-4-amine
2-溴-n-乙基-5-硝基-4-吡啶胺化学式
CAS
913642-07-6
化学式
C7H8BrN3O2
mdl
——
分子量
246.063
InChiKey
CJWGLCCOOXQJRC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    360.3±42.0 °C(Predicted)
  • 密度:
    1.677±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.6
  • 重原子数:
    13
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.29
  • 拓扑面积:
    70.7
  • 氢给体数:
    1
  • 氢受体数:
    4

SDS

SDS:a8d7c514dc3d25013fc4fe128db163da
查看

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Inhibitors of Akt Activity
    申请人:Heerding Dirk A.
    公开号:US20080318947A1
    公开(公告)日:2008-12-25
    Invented are novel 1H-imidazo[4,5-c]pyridin-2-yl compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
    本发明涉及一种新型的1H-咪唑并[4,5-c]吡啶-2-基化合物,其作为蛋白激酶B活性的抑制剂以及在癌症和关节炎治疗中的应用。
  • Aminofurazans as potent inhibitors of AKT kinase
    作者:Meagan B. Rouse、Mark A. Seefeld、Jack D. Leber、Kenneth C. McNulty、Lihui Sun、William H. Miller、ShuYun Zhang、Elisabeth A. Minthorn、Nestor O. Concha、Anthony E. Choudhry、Michael D. Schaber、Dirk A. Heerding
    DOI:10.1016/j.bmcl.2009.01.002
    日期:2009.3
    AKT inhibitors containing an imidazopyridine aminofurazan scaffold have been optimized. We have previously disclosed identification of the AKT inhibitor GSK690693, which has been evaluated in clinical trials in cancer patients. Herein we describe recent efforts focusing on investigating a distinct region of this scaffold that have afforded compounds (30 and 32) with comparable activity profiles to that of GSK690693.
  • WO2006/113837
    申请人:——
    公开号:——
    公开(公告)日:——
  • Discovery of Aminofurazan-azabenzimidazoles as Inhibitors of Rho-Kinase with High Kinase Selectivity and Antihypertensive Activity
    作者:Robert A. Stavenger、Haifeng Cui、Sarah E. Dowdell、Robert G. Franz、Dimitri E. Gaitanopoulos、Krista B. Goodman、Mark A. Hilfiker、Robert L. Ivy、Jack D. Leber、Joseph P. Marino,、Hye-Ja Oh、Andrew Q. Viet、Weiwei Xu、Guosen Ye、Daohua Zhang、Yongdong Zhao、Larry J. Jolivette、Martha S. Head、Simon F. Semus、Patricia A. Elkins、Robert B. Kirkpatrick、Edward Dul、Sanjay S. Khandekar、Tracey Yi、David K. Jung、Lois L. Wright、Gary K. Smith、David J. Behm、Christopher P. Doe、Ross Bentley、Zunxuan X. Chen、Erding Hu、Dennis Lee
    DOI:10.1021/jm060873p
    日期:2007.1.1
    The discovery, proposed binding mode, and optimization of a novel class of Rho-kinase inhibitors are presented. Appropriate substitution on the 6-position of the azabenzimidazole core provided subnanomolar enzyme potency in vitro while dramatically improving selectivity over a panel of other kinases. Pharmacokinetic data was obtained for the most potent and selective examples and one (6n) has been shown to lower blood pressure in a rat model of hypertension.
查看更多